3135 – CD34+CD19-CD22+ B-CELL PROGENITORS MIGHT UNDERLIE PHENOTYPIC ESCAPE IN PATIENTS TREATED WITH CD19-DIRECTED THERAPIES

نویسندگان

چکیده

CD19-directed immunotherapies have revolutionized the treatment of advanced B-ALL. Despite initial impressive rates complete remission (CR) many patients ultimately relapse. The fact that B-ALL successfully treated with T-cells eventually relapse, coupled early onset CD22 expression during B-cell development suggest pre-existing CD34+CD22+CD19- (pre)-leukemic cells could represent an “early progenitor origin-related” mechanism underlying phenotypic escape to immunotherapies. We demonstrate precedes CD19 development. CD34+CD19-CD22+ are found in diagnostic and relapsed BM samples ~70% patients, their frequency increases 2-fold CR after CD19-CAR T-cell therapy. Important, median before was 3-fold higher those who relapse immunotherapy (median follow-up 24 months). FISH analysis flow-sorted populations xenograft modeling revealed harbor genetic abnormalities present at diagnosis initiate leukemogenesis NSG mice. pre-leukemic progenitors underlie Our data reinforces ongoing clinical studies aimed simultaneously targeting as a strategy reduce CD19- relapses encourages implementation such CD34/CD19/CD22 panel flow cytometry laboratories for subsequent monitoring CD19-targeted

برای دانلود رایگان متن کامل این مقاله و بیش از 32 میلیون مقاله دیگر ابتدا ثبت نام کنید

اگر عضو سایت هستید لطفا وارد حساب کاربری خود شوید

منابع مشابه

Phase I study of a bispecific ligand-directed toxin targeting CD22 and CD19 (DT2219) for refractory B-cell malignancies.

PURPOSE The novel bispecific ligand-directed toxin (BLT) DT2219 consists of a recombinant fusion between the catalytic and translocation enhancing domain of diphtheria toxin (DT) and bispecific single-chain variable fragments (scFV) of antibodies targeting human CD19 and CD22. We conducted a phase I dose-escalation study to assess the safety, maximum tolerated dose, and preliminary efficacy of ...

متن کامل

Catch me if you can: Leukemia Escape after CD19-Directed T Cell Immunotherapies

Immunotherapy is the revolution in cancer treatment of this last decade. Among multiple approaches able to harness the power of the immune system against cancer, T cell based immunotherapies represent one of the most successful examples. In particular, biotechnological engineering of protein structures, like the T cell receptor or the immunoglobulins, allowed the generation of synthetic peptide...

متن کامل

Radioimmunotherapy using 131I-labeled anti-CD22 monoclonal antibody (LL2) in patients with previously treated B-cell lymphomas.

Experience in using rapidly internalizing antibodies, such as the anti-CD22 antibody, for radioimmunotherapy of B-cell lymphomas is still limited. The present study was conducted to assess the efficacy and toxicity of a 131I-labeled anti-CD22 monoclonal antibody (mAb), LL2, in patients with B-cell lymphomas failing first- or second-line chemotherapy. Eligible patients were required to have meas...

متن کامل

Immunoglobulin recombinase gene activity is modulated reciprocally by interleukin 7 and CD19 in B cell progenitors

Bone marrow stromal cells promote B cell development involving recombinase gene-directed rearrangement of the immunoglobulin genes. We observed that the stromal cell-derived cytokine interleukin 7 (IL-7) enhances the expression of CD19 molecules on progenitor B-lineage cells in human bone marrow samples and downregulates the expression of terminal deoxynucleotidyl transferase (TdT) and the reco...

متن کامل

ذخیره در منابع من


  با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید

ژورنال

عنوان ژورنال: Experimental Hematology

سال: 2022

ISSN: ['1873-2399', '0301-472X']

DOI: https://doi.org/10.1016/j.exphem.2022.07.191